AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (52.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Biomimetic mineralized nanocarriers based on reversal of cholesterol reprogramming against aggressive tumors by enhanced immunotherapy

Liyuan Guan1,§Zhaoxu Meng2,§Xiaoshu Zhang3,§Xihang Ren1Yanzhu Wang1Yake Qi1Luhua Liang2Luyao Wang2Zhenjun Chen4Linghe Zang5Zhou Li2He Lian2 ( )Xiu Dong6 ( )Yiping Mu4 ( )
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
Department of Biomedical Engineering, School of Medical devices, Shenyang Pharmaceutical University, Shenyang 110016, China
Department of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China
Central Hospital Affiliated to Shenyang Medical College, Shenyang 110024, China
Institute of Life Science and Bio-pharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China
College of integrated Traditional Chinese Medicine and Western medicine, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China

§ Liyuan Guan, Zhaoxu Meng, and Xiaoshu Zhang contributed equally to this work.

Show Author Information

Abstract

The occurrence and development of cancer are closely related to dysregulation of cholesterol metabolism. Therefore, targeting cholesterol metabolism presents a novel diagnosis and treatment strategy for cancer. In this study, a nanosystem (AVA-COD@Fe) exhibiting dual enzymatic activity was developed through a biomimetic mineralization approach. Cholesterol oxidase (COD) facilitated the consumption of cholesterol, thereby impairing the migratory capacity of tumor cells and diminishing resilience on oxidative stress. Concurrently, COD catalyzed the production of hydrogen peroxide (H2O2), which compensated for inadequate levels of tumor cells, thereby enhancing ferroptosis and ultimately inhibiting tumor growth and metastasis. Meanwhile, as an immune sensitizer, avasimibe altered cholesterol distribution, and promoted the infiltration and vitality of cytotoxic T lymphocytes into tumors jointly with immunogenic cell death (ICD) induced by ferroptosis, and enhanced anti-tumor immunity. To elicit significant immune memory effects, this nanosystem was further combined with the anti-programmed cell death protein ligand-1 antibody, which effectively inhibited the growth of both primary and metastatic tumors, and demonstrated a robust systemic anti-tumor immune response. This study addressed modulation of tumor cell cholesterol metabolism as a strategic entry point for tumor suppression, significantly curtailing tumor progression, and activating systemic immune responses, thereby offering a new perspective for future cancer therapies.

Graphical Abstract

The nanosystem (AVA-COD@Fe) effectively reversed the cholesterol metabolic reprogramming in tumor cells, weakened motility and promoted ferroptosis, and ultimately inhibited their growth and metastasis. The immune sensitizer avasimibe altered cholesterol distribution and enhanced CD8+ T cell activity to enhance anti-tumor immunity. The combination of the nanosystem and αPD-L1 obtained a highly effective systemic anti-tumor immunotherapy effect.

Electronic Supplementary Material

Download File(s)
8181_ESM.pdf (6.4 MB)

References

【1】
【1】
 
 
Nano Research
Article number: 94908181

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Guan L, Meng Z, Zhang X, et al. Biomimetic mineralized nanocarriers based on reversal of cholesterol reprogramming against aggressive tumors by enhanced immunotherapy. Nano Research, 2025, 18(12): 94908181. https://doi.org/10.26599/NR.2025.94908181
Topics:

1303

Views

165

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 19 August 2025
Revised: 15 October 2025
Accepted: 20 October 2025
Published: 21 November 2025
© The Author(s) 2025. Published by Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/).